
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc. is positioned favorably in the biotech sector due to the promising interim biomarker results and lung function data associated with its lead product candidates, GRI-0621 and GRI-0803. The company's current valuation reflects an attractive opportunity, as it maintains a BUY rating while indicating significant upside potential based on net present value (NPV) analyses. Additionally, the observed positive impacts on fibrogenesis, fibrolysis, and safety metrics from recent data support the company's trajectory towards commercializing impactful therapies for serious autoimmune and inflammatory disorders.
Bears say
GRI Bio Inc reported a net loss of $3.4 million, or an earnings per share (EPS) of $(1.28), which significantly exceeded both personal estimates of $(1.11) and consensus expectations of $(0.93). Additionally, the company experienced another net loss of $3.9 million with an EPS of $(7.72), again falling short of projections that were $(4.08) and $(5.44) respectively, indicating consistently poorer financial performance than anticipated. Key risks impacting the company's financial outlook include balance sheet and liquidity challenges, potential failures in clinical trial outcomes, and the pressures of regulatory approvals, all of which contribute to a pessimistic view of GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares